Fenwick Represents Impel Pharmaceuticals in Sale to JN BIDCO LLC

Fenwick is representing Impel Pharmaceuticals Inc. (OTCQX: IMPL), a commercial-stage biopharmaceutical company, in its sale to JN BIDCO LLC, which will serve as the "stalking horse" bidder to acquire Impel and its assets.

In accordance with the sale process under Section 363 of the Bankruptcy Code, Impel will solicit competing bids from interested parties, to achieve the highest and best value for its assets. Impel seeks to complete the sale process in the first quarter of 2024, with any sale subject to court approval. More information can be obtained from Impel Pharmaceuticals announcement.

The Fenwick transaction team includes corporate partners Alan Smith, Ethan Skerry, Ryan Mitteness and Eric Shedlosky and associates Matt McCabe, Frances Fuqua and Seena Razavi; technology transactions partner Jonathan Millard and associate Trevor Snider; executive compensation and employee benefits partner Nancy Chen and associate Jonathan Stephenson; patent partner Dan Becker and associate Dr. Hayan Yoon; trademark partner Connie Ellerbach and associate Matthew Slevin; and tax partner William Skinner.

Corporate partner Amanda Rose and associates Karin Hjorth and Angelo Angelino have done substantial historical work for Impel Pharmaceuticals.